drugset / Trial / NCT07098117

A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Pharmacokinetic Profile of Single and Multiple Dose Escalation Topical Dermal Administration of SHR0302 Alkali Gel in Healthy Subjects

NCT07098117

Phase 1 Completed 32 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is divided into two parts, the first part is a single-dose dose escalation trial (SAD) in healthy subjects; The second part is a multiple-dose dose escalation trial (MAD) in healthy subjects.

Timeline

Start
2024-06-19
Primary completion
2024-07-31
Completion
2024-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR0302 Unknown Topical

Indications

No indication recorded.